Furthermore, the current intermittent parathyroid hormone (PTH) anabolic treatment combined with TNF blockers fail to reduce the erosion volume in patients with established RA but with the controlled disease activity [117], reflecting a total uncoupling between bone resorption and bone formation, which is still not fully understood. The gene discussed is PTH; the disease is rheumatoid arthritis.